Vanda Pharmaceuticals at H.C. Wainwright conference: pipeline broadens

Vanda ended Q2 2026 with about $170 million in cash, down from $260 million at the start of the year, while levered free cash flow was negative $143 million over the trailing 12 months amid elevated development and launch spending. Fanapt revenue and prescriptions rose 30% year over year to an annual run rate above $100 million, and Vanda expects BYSANTI's mid-30% gross-to-net profile versus roughly 50% for Fanapt to improve unit economics following its planned year-end 2026 launch. Key upside catalysts include year-end Phase III data for NEREUS in GLP-1-related nausea and vomiting, where Phase II vomiting incidence was about 30% versus 60% on placebo, plus a December PDUFA decision for Qulmilza; execution, clinical-readout and cash-burn risks remain material.

Analysis

VNDA’s central valuation question is not pipeline breadth but whether cash generation can bridge the commercialization gap without equity dilution. The current cash balance against trailing free-cash-flow burn implies a sub-18-month runway absent a material expense step-down or revenue inflection; therefore, the market should discount 2028 opportunities heavily and focus on quarterly cash use beginning with Q3. Management’s expense-reduction narrative is not yet independently validated, and a financing before the MDD program is de-risked would likely cap upside through 2027.

BYSANTI’s better net-price realization is economically attractive, but it is primarily a conversion and gross-to-net optimization story rather than proof of incremental franchise demand. The key risk is that payer access, formulary positioning and switching friction prevent the company from retaining enough patients ahead of Fanapt exclusivity loss; a nominal improvement in net realization can be offset by lower gross pricing, rebates, or generic leakage. The relevant 1-3 month KPI is not qualitative launch feedback but new-to-brand prescriptions, switch persistence, gross-to-net progression and sales-force productivity.

The late-2026 event stack creates a binary catalyst premium, with the GLP-1 nausea study the only program that could alter the company’s revenue trajectory materially in the near term. However, efficacy alone would not establish value: payers and GLP-1 manufacturers must view antiemetic reimbursement as cheaper than discontinuation, and the addressable population may be limited to patients with severe symptoms rather than universal prophylaxis. A positive result could create strategic-interest optionality from LLY or NVO ecosystem participants, but a negative or equivocal readout leaves VNDA with an elevated fixed cost base and a mature-product revenue concentration problem.

ANAB is a second-order watch rather than a direct sympathy trade. Any approval and commercialization progress for Qulmilza could create milestone or royalty value for AnaptysBio depending on the license economics, but investors should verify the disclosed contract terms and whether contingent payments are already reflected in ANAB’s valuation before positioning.

Key Decisions for Investors

• Maintain VNDA as a watchlist/event-driven name rather than a core long until Q3 cash burn and 2027 operating-expense guidance demonstrate a credible runway beyond the first half of 2028. A quarterly cash decline materially below the recent run-rate, without a revenue miss, is the first confirmation point.
• For a high-risk biotech sleeve, consider a small VNDA long only after confirmation that the GLP-1 nausea Phase III endpoint is met and management provides a payer-access and filing timeline. Size for binary risk; a failed study or cash-runway guidance below 12 months invalidates the thesis.
• Avoid underwriting BYSANTI as net new revenue until post-launch data show that switch volume exceeds Fanapt attrition and gross-to-net improves as guided. If 2027 franchise revenue fails to stabilize despite the launch, the appropriate expression is short VNDA versus XBI, subject to borrow availability and catalyst hedging.
• Set an ANAB alert around the Qulmilza regulatory decision and review its licensing disclosures for milestone/royalty participation. Initiate no position solely on VNDA’s presentation because the economic pass-through to ANAB is not established in the supplied data.
• Monitor LLY and NVO only as indirect read-throughs: sustained GLP-1 discontinuation concerns or a positive adjunctive-nausea dataset may modestly improve adherence economics, but the impact is unlikely to be material enough for a standalone trade absent partnership or reimbursement evidence.